Background: We have been in need of a sign of hope in the fight against SARS-CoV-2 as it runs from city to city overwhelming health systems. The majority of patients will be either asymptomatic or have only mild disease. These ...
Background: In end-stage renal disease (ESRD) patients on hemodialysis (HD), infection is the second most common cause of mortality after cardiovascular disease (Sarnik 2000). Because of the systemic inflammation and increased capillary permeability, septic patients are at significant risk for fluid ...
Background: Despite the initial excitement around the use of chloroquine (CQ) and hydroxychloroquine (HCQ), there is mounting evidence that neither drug is effective in COVID-19 treatment. Laboratory studies have shown antiviral and immunomodulatory properties in vitro but these have not ...
Background: Convalescent plasma therapy is not a new or novel therapeutic option. It involves taking the plasma from patients who have recovered from an illness and using it to treat patients who currently have the same illness. This approach has ...
Background: We have covered the two previous RCTs on remdesivir on REBEL EM (RCT #1 and RCT #2). In the first trial by Wang et al , there was no statically significant improvement in clinical outcomes, but, there were trends ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
